Newsroom

News & Press Releases


COBRA PzF NanoCoated Coronary Stent Demonstrates Exceptional Long-Term Safety and Low ID-TLR at Five Years in Highly Complex Patients Undergoing PCI

San Antonio - May 13 2021

Positive results from the landmark PzF SHIELD IDE clinical trial reinforce safe and effective use in a real-world clinical practice of the world's first non-drug-eluting, nanocoated coronary stent.


Browse Our Archives

Press Release

San Antonio, TX – June 1, 2020

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

The COBRA REDUCE randomized control trial is a first-of-its-kind study designed to evaluate ultra-short DAPT in PCI patients at high bleeding risk with COBRA PzF NCS with 14-day DAPT compared to drug-eluting stents with 3 or 6 months DAPT.

Read Press Release